Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jupiter Life Line Hospitals Limited (JLHL.NS)
Mumbai, IN
Jupiter Life Line Hospitals Limited, established in Mumbai, India, in 2002, operates as a multi-specialty healthcare provider throughout the country under its Jupiter brand. The company delivers a comprehensive range of medical and surgical services spanning numerous disciplines. These include diverse surgical fields such as bariatric, cardiac, general, minimal access, HPB, surgical gastroenterology, neurosurgery, organ transplant, orthopedics (including robotic knee replacement), and plastic and cosmetic surgery. Additionally, Jupiter Life Line Hospitals offers specialized care in cardiology, chest medicine, dental care, dermatology, ENT, endocrinology and diabetes, gastroenterology, hematology and bone marrow transplantation, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, nutrition and dietetics, obstetrics and gynecology, oncology, ophthalmology, pediatrics, pain management, rehabilitation, and rheumatology. Beyond its healthcare operations, the company also manages the Fortune Park Lake City Hotel located in Thane.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.87% | +7.46% | +4.38% | +8.52% | -6.65% | -3.98% | -5.67% | +24.38% | +24.38% | +24.38% | +24.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+18.9% ★ Q1'26: +17.1% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+0.4% Q1'26: +12.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+9.0% Q1'26: -10.4% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+17.0% ★ Q1'26: +17.0% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+12.0% ★ Q1'26: +12.4% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×1.70× ★ Q1'26: 1.64× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 4 EPS Ana. |
Mar 2027 5 Rev. Ana. 4 EPS Ana. |
Mar 2028 5 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
10.70B
est: 10.66B (+0.4%)
|
12.62B
est: 12.85B (-1.8%)
|
14.86B
14.74B – 15.00B
+15.7% YoY
|
18.10B
17.70B – 18.36B
+21.8% YoY
|
21.49B
20.94B – 22.32B
+18.7% YoY
|
30.79B
30.06B – 31.63B
+43.3% YoY
|
| EBITDA |
2.61B
est: 4.07B (-35.9%)
|
3.25B
est: 4.91B (-33.7%)
|
5.68B
5.63B – 5.73B
+15.7% YoY
|
6.91B
6.76B – 7.01B
+21.8% YoY
|
8.21B
8.00B – 8.52B
+18.7% YoY
|
11.76B
11.48B – 12.08B
+43.3% YoY
|
| EBIT |
2.18B
est: 3.78B (-42.3%)
|
2.68B
est: 4.56B (-41.1%)
|
5.27B
5.23B – 5.32B
+15.7% YoY
|
6.42B
6.28B – 6.51B
+21.8% YoY
|
7.62B
7.42B – 7.91B
+18.7% YoY
|
10.92B
10.66B – 11.22B
+43.3% YoY
|
| Net Income |
1.77B
est: 1.77B (-0.2%)
|
1.93B
est: 2.04B (-5.3%)
|
1.94B
1.80B – 2.01B
-4.9% YoY
|
2.21B
1.98B – 2.41B
+13.9% YoY
|
2.83B
2.48B – 3.39B
+27.9% YoY
|
4.17B
4.04B – 4.32B
+47.6% YoY
|
| SGA |
2.72B
est: 2.63B (+3.6%)
|
3.12B
est: 3.17B (-1.5%)
|
3.67B
3.64B – 3.70B
+15.7% YoY
|
4.47B
4.37B – 4.53B
+21.8% YoY
|
5.30B
5.17B – 5.50B
+18.7% YoY
|
7.59B
7.41B – 7.80B
+43.3% YoY
|
| EPS |
28.44
est: 27.00 (+5.3%)
|
29.47
est: 31.13 (-5.3%)
|
29.22
27.48 – 30.61
-6.2% YoY
|
34.05
30.21 – 36.75
+16.5% YoY
|
44.60
37.87 – 51.73
+31.0% YoY
|
63.60
61.63 – 65.87
+42.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 201.7K | 0.65% |
| 2 | WisdomTree India Earnings Fund EPI | 0.01% | 256.4K | 0.84% |
| 3 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.00% | 2.6K | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ajay Pratap Thakker | Chairman & MD | 39M | — |
| Ankit Ajay Thakker | Joint MD, Chief Executive Officer & Executive Director | 26M | — |
| Harshad Purani | Chief Financial Officer and President of Administration & Head of Corporate Social Responsibility | — | male |
| Manisha Shah | Group Chief Human Resources Officer | — | female |
| Neelesh Shinde | Group Chief Technical Officer & Head of Projects | — | male |
| Rajendra Patankar | Chief Executive Officer of Pune Hospital | — | — |
| Shilpa Tatake | Chief Executive Officer of Thane | — | — |
| Suma Vinayak Upparatti | Company Secretary & Compliance Officer | — | female |
| Sumit Goda | Chief Commercial Officer | — | male |
| Anand Apte | Chief Business & Strategy Officer and Investor Relation Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JLHL.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
